Study Provides Preliminary Evidence in Favor of a New Type 1 Diabetes Treatment

A new study led by researchers at the University of Chicago Medicine and Indiana University suggests that an existing drug could be repurposed to treat type 1 diabetes, potentially reducing dependence on insulin as the sole treatment. The research centers on a medication known as α-difluoromethylornithine (DFMO), which inhibits an enzyme that plays a key role in cellular metabolism.

The DFMO for this research was supplied by UF startup Panbela Therapeutics, a clinical-stage biopharmaceutical company developing disruptive therapeutics for urgent unmet medical needs. The results of the trial indicated that the drug is safe for type 1 diabetes patients and can help keep insulin levels stable by protecting beta cells.

Read more about Study provides preliminary evidence in favor of a new type 1 diabetes treatment.